Novartis in Society Integrated Report 2024
This report covers our business, strategy and ESG performance. It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards.
Annual Report 2024 and US Securities & Exchange Commission Form 20-F 2024
These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerland and the Securities and Exchange Commission in the US.
Novartis shareholders may receive a hard copy of either of these documents, each of which contains our complete audited financial statements, free of charge, upon request.
Annual Report 2024 (PDF 3.5 MB) | Form 20-F 2024 (PDF 3.4 MB)
Other reporting documents
Additional documents, including downloadable data from the Novartis in Society Integrated Report and additional regulatory disclosures.
Investor relations
Policies and positions
As part of our ongoing commitment to transparency, we publish our positions on various issues affecting our business. We are also transparent about our values and behaviors, our approach to managing ethical decisions, and the standards we expect of our suppliers. This section includes many of the policies, codes, guidelines and commitments that govern the company's activities.
Positions
- Animal research (PDF 0.2 MB)
- Clinical study transparency (PDF 0.2 MB)
- Medicines for Patients with Rare Diseases (PDF 0.2 MB)
- Post-trial Access (PDF 0.1 MB)
- Pre-Approval Access to Novartis Products through MAPs (PDF 0.3 MB)
- Responsible Clinical Trials (PDF 0.1 MB)
- Novartis Commitment to Diversity in Clinical Trials (PDF 0.2 MB)
- Novartis Position on Investigator Initiated Trials (IITs) and Investigator Initiated Research (IIRs) (PDF 0.2 MB)
- Position on Scientific Publications (PDF 0.2 MB)
Codes, Policies and Guidelines
- Novartis Third Party Code v. 1.0 (PDF 0.6 MB)*
- Novartis Third Party Code v. 2.0 (PDF 0.3 MB)**
- Novartis Third Party Code v. 3.0 (PDF 0.4 MB)***
- Novartis Third Party Code v. 4.0 (PDF 0.5 MB)****
- Novartis Minimum Information Security Controls for Suppliers (PDF 0.5 MB)
- Novartis No Purchase Order (PO) No Pay Policy (PDF 0.1 MB)
* v1.0 remains valid for contracts entered into up to October 31, 2020 unless the contract stipulates that the most up-to-date TPC version is to be adhered to.
** v2.0 remains valid for contracts entered into up to December 31, 2022 unless the contract stipulates that the most up-to-date TPC version is to be adhered to.
*** v3.0 remains valid for contracts entered into up to June 30, 2025 unless the contract stipulates that the most up-to-date TPC version is to be adhered to.
**** v4.0 is valid for contracts entered into as from July 1, 2025
ESG index
Novartis welcomes interest from investors and other stakeholders concerned ESG topics and we aim to report comprehensively and transparently on our objectives and progress. Our ESG index shows where disclosures on key topics can be found across our publications and website.